OP0014 INTENSITY OF SMOKING (PACK-YEARS) IS ASSOCIATED WITH POOR THERAPY RESPONSE IN RA PATIENTS STARTING THEIR FIRST ANTI-TNF TREATMENT. DATA FROM SSATG, A BIOLOGICS REGISTER IN SOUTHERN SWEDEN
M. Söderlin 1,*P. Geborek 1
1Section for Rheumatology, Department of Clinical Sciences, Lund, Sweden
Background: Smoking has been associated with higher disease activity and a poor response to anti-TNF therapy in rheumatoid arthritis (RA) patients.
Objectives: To study the effect of intensity of smoking (pack-years) on response to therapy and the different individual components in EULAR response criteria, Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI).
Methods: RA patients in the South Swedish Arthritis Treatment Group (SSATG) register, a voluntary rheumatological biologics register, were sent a questionnaire in 2005 that covered smoking habits. We wanted to examine if smoking exposure (pack-years) correlated with EULAR, SDAI or CDAI response or the individual components of the DAS28, SDAI or CDAI.
Results: A total of 941/1229 subjects (77%) answered the smoking questions in the questionnaire (infliximab, n = 537 (57%); etanercept, n = 322 (34%); adalimumab, n = 82 (9%)). A univariate logistic regression showed that a smoking history of 11-20 pack-years predicted a poor EULAR response at 3 months (OR 0.58, 95% CI 0.37-0.92, p=0.022). In the multivariate analyses, a smoking history of 11-20 pack-years emerged as an independent predictive factor for poor SDAI response at 6 months (OR 0.47 (95% CI 0.25-0.89), p=0.02) and at 12 months (OR 0.38, (95% CI 0.18-0.82), p=0.013) and CDAI response at 6 months (OR 0.48 (95% CI 0.26-0.86), p=0.014) when omitting smoking status at baseline from the regression model. Pack-year history did not emerge as an independent predictive factor for EULAR response at any time point. Smokers had higher CRP and worse scores for global health at 3 months of follow-up. There were no significant differences in drug survival stratified according to pack-year history.
Conclusion: A smoking history of 11-20 pack-years had a negative prognostic effect using EULAR, SDAI and CDAI response as outcome up to 12 months follow-up, but the results depended on outcome measure used. The results indicate that cessation of smoking may be important for RA patients starting anti-TNF treatment.
Disclosure of Interest: None declared